Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|May 23, 2020
- May 2020
- Volume 90
- Issue 5
Pharmacy Times digital issue (May 2020)
Pharmacy Times™ digital issue (May 2020)
Advertisement
Articles in this issue
over 6 years ago
Interactives: Case Studies (May 2020)over 6 years ago
Pet Peeves (May 2020)over 6 years ago
Palforzia From Aimmune Therapeutics Incover 6 years ago
Spread the Word About Medication Therapy Management Servicesover 6 years ago
Acne Can Be Troublesome But Responds to Treatmentover 6 years ago
Drug Manufacturers Must Increase Transparency During Pandemicover 6 years ago
Generic Products (May 2020)Advertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Alcohol and GLP-1 Therapy: Key Counseling Points for Pharmacists
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5